Access comprehensive financial analyses and make smarter investments - get the Manual of Investments on Amazon!

LLY

Understanding Eli Lilly and Company (LLY) Stock for Investors

Shares of Health Care sector company Eli Lilly and moved 2.6% today, and are now trading at a price of $1015.93. The Large-Cap stock's daily volume was 2,811,311 compared to its average volume of 3,107,770. The S&P 500 index returned a 1.0% performance.

Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceutical products in the United States, Europe, China, Japan, and internationally. The company is based in Indianapolis and has 50,000 full time employees. Its market capitalization is $905,946,791,936. Eli Lilly and currently offers its equity investors a dividend that yields 0.6% per year.

29 analysts are following Eli Lilly and and have set target prices ranging from $850.0 to $1500.0 per share. On average, they have given the company a rating of buy. At today's prices, LLY is trading -15.98% away from its average analyst target price of $1209.14 per share.

Over the last year, LLY's share price has increased by 38.3%, which represents a difference of 12.7% when compared to the S&P 500. The stock's 52 week high is $1133.95 per share whereas its 52 week low is $623.78. With average free cash flows of $5.07 Billion that have been growing at an average rate of 9.9% over the last 5 years, Eli Lilly and is in a position to continue its strong stock performance trend.

Date Reported Cash Flow from Operations ($ k) Capital expenditures ($ k) Free Cash Flow ($ k) YoY Growth (%)
2025 16,813,000 7,841,000 8,972,000 138.62
2024 8,818,000 5,058,000 3,760,000 374.75
2023 4,240,000 3,448,000 792,000 -86.18
2022 7,585,700 1,854,300 5,731,400 -5.36
2021 7,365,900 1,309,800 6,056,100 18.48
2020 6,499,600 1,387,900 5,111,700
The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.

IN FOCUS